Allogene Therapeutics Inc (ALLO) - Total Assets
Based on the latest financial reports, Allogene Therapeutics Inc (ALLO) holds total assets worth $439.77 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Allogene Therapeutics Inc's book value for net asset value and shareholders' equity analysis.
Allogene Therapeutics Inc - Total Assets Trend (2017–2024)
This chart illustrates how Allogene Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Allogene Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Allogene Therapeutics Inc's total assets of $439.77 Million consist of 55.3% current assets and 44.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.7% |
| Accounts Receivable | $1.90 Million | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Allogene Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALLO market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Allogene Therapeutics Inc's current assets represent 55.3% of total assets in 2024, an increase from 0.0% in 2017.
- Cash Position: Cash and equivalents constituted 13.7% of total assets in 2024, up from 0.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Allogene Therapeutics Inc Competitors by Total Assets
Key competitors of Allogene Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Allogene Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.19 | 9.35 | 8.96 |
| Quick Ratio | 8.19 | 9.35 | 8.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $228.89 Million | $271.84 Million | $750.81 Million |
Allogene Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Allogene Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.28 |
| Latest Market Cap to Assets Ratio | 0.74 |
| Asset Growth Rate (YoY) | -14.6% |
| Total Assets | $548.71 Million |
| Market Capitalization | $404.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values Allogene Therapeutics Inc's assets below their book value (0.74x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Allogene Therapeutics Inc's assets decreased by 14.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Allogene Therapeutics Inc (2017–2024)
The table below shows the annual total assets of Allogene Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $548.71 Million | -14.64% |
| 2023-12-31 | $642.84 Million | -21.76% |
| 2022-12-31 | $821.58 Million | -21.82% |
| 2021-12-31 | $1.05 Billion | -14.42% |
| 2020-12-31 | $1.23 Billion | +71.05% |
| 2019-12-31 | $717.80 Million | -7.24% |
| 2018-12-31 | $773.86 Million | -- |
| 2017-12-31 | $0.00 | -- |
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell a… Read more